In this test, HLA class II-expressing AML cells were enriched by MACS, and EBV-LCL, generated from PBMCs when entering clinical remission after intensive chemotherapy, expressed high levels of HLA class II and wild-type DNMT3A. Clone 1.5.F1DNMT3A specifically secreted IFN-γ upon stimulation with AML cells, but not EBV-LCL. This evidence concerns the gene DNMT3A and acute myeloid leukemia.